SCHEMBL30103046

SCHEMBL30103046

COc1cccc(-c2nccc(CBr)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK4 Q9HAZ1 13/20 0.62
▸ DYRK1A Q13627 4/20 0.62
▸ CYP1A2 P05177 12/20 0.55
▸ CYP3A4 P08684 11/20 0.55
▸ CYP2D6 P10635 10/20 0.55
▸ CYP2C19 P33261 10/20 0.55
▸ LMNA P02545 6/20 0.55
▸ TSHR P16473 5/20 0.55
▸ TP53 P04637 5/20 0.55
▸ ALDH1A1 P00352 4/20 0.55
▸ MAPK1 P28482 4/20 0.55
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ ALOX15 P16050 3/20 0.55
▸ TDP1 Q9NUW8 3/20 0.53
▸ MAPT P10636 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ USP2 O75604 4/20 0.52
▸ CYP2C9 P11712 4/20 0.52
▸ CYP19A1 P11511 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103034 0.82 NPC1 (0.56) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL30103016 0.81 CYP1A2 (0.52) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL28029638 0.80 CLK4 (0.72) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL2666349 0.79 CLK4 (0.70) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL31230014 0.79 CLK4 (0.70) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL25269044 0.79 CLK4 (0.70) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL12302829 0.78 CLK4 (1.00) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL25220297 0.78 CLK4 (0.68) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL31230006 0.78 CLK4 (0.68) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL30447335 0.78 CLK4 (0.68) CLK4DYRK1ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115448913-A Bicyclic compounds for the treatment of EP2, EP4 receptor mediated diseases 武汉人福创新药物研发中心有限公司 2022-12-09 — — CN disclosed
Send feedback